GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benitec Biopharma Inc (NAS:BNTC) » Definitions » 5-Year Yield-on-Cost %

Benitec Biopharma (Benitec Biopharma) 5-Year Yield-on-Cost % : 0.00 (As of May. 20, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Benitec Biopharma 5-Year Yield-on-Cost %?

Benitec Biopharma's yield on cost for the quarter that ended in Mar. 2024 was 0.00.


The historical rank and industry rank for Benitec Biopharma's 5-Year Yield-on-Cost % or its related term are showing as below:



BNTC's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.64
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Benitec Biopharma's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Benitec Biopharma's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Benitec Biopharma's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benitec Biopharma's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Benitec Biopharma's 5-Year Yield-on-Cost % falls into.



Benitec Biopharma 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Benitec Biopharma is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Benitec Biopharma  (NAS:BNTC) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Benitec Biopharma 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Benitec Biopharma's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Benitec Biopharma (Benitec Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
3940 Trust Way, Hayward, CA, USA, 94545
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.
Executives
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Megan Boston director, officer: Executive Director LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000
Steven Michael Oliveira 10 percent owner 18 FIELDSTONE COURT, NEW CITY NY 10956
Patrick Soon-shiong 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Edward F Smith director C/O POLYMEDIX, INC., 3701 MARKET STREET, PHILADELPHIA PA 19104
California Capital Equity, Llc 10 percent owner 10182 CULVER BOULEVARD, CULVER CITY CA 90232
Nant Capital, Llc 10 percent owner 9922 JEFFERSON BOULEVARD, CULVER CITY CA 90232
Peter Francis director LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000
Jerel A. Banks director, officer: Chief Executive Officer LEVEL 14, 114 WILLIAM ST, MELBOURNE, VIC C3 3000